Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia
The Prostate2020Vol. 80(10), pp. 731–741
Citations Over TimeTop 10% of 2020 papers
Petra Popovics, Wisam N. Awadallah, Sarah E. Kohrt, Thomas C. Case, Nicole L. Miller, Emily A. Ricke, Wei Huang, Marisol Ramirez‐Solano, Qi Liu, Chad M. Vezina, Robert J. Matusik, William A. Ricke, Magdalena M. Grabowska
Abstract
OPN is more abundant in prostates of men with S-BPH compared to men with I-BPH. OPN secretion is stimulated by proinflammatory cytokines, and OPN acts directly on stromal cells to drive the synthesis of proinflammatory mRNAs. Pharmacological manipulation of prostatic OPN may have the potential to reduce LUTS by inhibiting both inflammatory and fibrotic pathways.
Related Papers
- → Tissue specificity and developmental expression of rat osteopontin(1987)316 cited
- Drug choices reviewed for benign prostatic hyperplasia(2016)
- Expression of osteopontin in colon cancer tissue and detection of osteopontin in serum(2007)
- Drug choices reviewed for benign prostatic hyperplasia : review(2016)
- → UP-3.047: Relationship between Lower Urinary Tract Symptoms and Intraprostatic Inflammation for Patients with Benign Prostatic Hyperplasia(2009)